Novo, Nordisk

Novo Nordisk Wins FDA Nod for Weekly Sogroya in Turner Syndrome as Buyback Passes DKK 12 Billion

Published on 11/20/2026 at 20:01 | Editorial boerse-global.de
FDA clears once-weekly Sogroya for Turner syndrome short stature in kids 2.5 and older, its fifth pediatric growth indication; Novo shares closed down 1.7%.
Novo, Nordisk, Wins, FDA, Nod, Weekly, Sogroya, Turner, Syndrome, Buyback Illustration mit AI erstellt.

Novo Nordisk's growth hormone Sogroya has secured US approval for children with Turner syndrome, opening a fifth pediatric growth indication for the once-weekly injection — a filing that lands alongside a steady drip of pipeline news and an ongoing share repurchase program.

The FDA cleared Sogroya for children aged 2.5 years and older with short stature caused by the condition. It becomes the first long-acting, weekly-dosed growth hormone available in the US for this patient group. Sogroya is now greenlit for five growth-related disorders in children, on top of its existing approval for adults with growth hormone deficiency.

REAL8: Convenience Gains, but Slower Growth Than Daily Shots

The label rests on the REAL8 trial, which enrolled 105 children. One arm received weekly Sogroya; the other was given daily somatropin. Dosing matters when reading the comparison — the somatropin dose used in the study sat below the maximum permitted in the US.

At 52 weeks, annualized growth velocity reached 8.9 centimeters per year with Sogroya versus 9.7 centimeters in the somatropin arm. The weekly regimen therefore cuts the number of injections without demonstrating faster growth than daily treatment. Commonly reported side effects included respiratory and ear infections, fever, diarrhea and vomiting, along with injection-site reactions. A two-year extension of the study, intended to gather further safety data, is under way.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Commercial uptake will hinge on when the product reaches the US market, the reimbursement terms insurers set, and how readily families and clinicians embrace a weekly schedule. Investors gave the news a muted reception: Novo Nordisk shares closed the session down 1.7%.

Buyback Tally Reaches DKK 12.1 Billion

Separately, the company reported on Monday the repurchase of 1.13 million B shares for roughly DKK 310 million. Since February 4, Novo Nordisk has bought back about 43.7 million B shares, a total of some DKK 12.1 billion.

European Clearance for FREHEMGO

Brussels added to the flow of announcements. On November 13 the European Commission granted FREHEMGO marketing authorization for routine prophylaxis in hemophilia A, covering adults and children with or without inhibitors. Novo Nordisk expects the first European launches next year.

CagriSema Data Cuts Both Ways

The pipeline story extended to CagriSema. On November 14 Novo Nordisk released phase 3 results from REDEFINE 9, estimating mean weight loss of 20.7% and 21.0% for the two lower-dose groups, against 2.0% for placebo. Those estimates are pegged to week 68 and assume participants stayed on treatment.

A post-hoc analysis of REDEFINE 1, published on the Sunday, showed that 67.8% of CagriSema-treated patients responded early to therapy. Within that group, observed mean weight loss through week 68 came in at 25.4%. The retrospective analysis is intended for hypothesis generation only.

Taken together, the week's developments sketch a company widening its label reach in growth disorders and hemophilia while leaning on regular buybacks — even as the equity market stayed cautious on the Turner syndrome approval itself.

Ad

Novo Nordisk Stock: New Analysis - 20 November

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

Disclaimer...
en | DK0062498333 | NOVO | boerse | 70541005 |